Spark Therapeutics' $4.8B deal confirmed as biggest-ever VC-backed exit in Philly - Technical.ly Philly

Business

Mar. 1, 2019 1:21 pm

Spark Therapeutics’ $4.8B deal confirmed as biggest-ever VC-backed exit in Philly

Quick update on this week's news: The University City life sciences company's acquisition by Swiss pharma giant Roche is the biggest acquisition ever of a VC-backed company within city limits, per PitchBook and PACT.

Founded in 2013, the UCity company announced its acquisition this week.

(Courtesy photo)

The eye-popping $4.8 billion sticker price on Spark Therapeutics’ acquisition deal with Roche announced on Monday is shaping up to be the largest exit ever within city limits for a venture-backed company, according to data from financial data provider PitchBook and the Philadelphia Alliance for Capital and Technologies (PACT).

“Filtering down to just Philadelphia proper does reveal that Spark Therapeutics, once the deal closes, will be the biggest exit ever for Philly-based venture-backed exits,” the company said in an email, citing data from an upcoming report.

According to the Seattle-based company’s data, the current holder of the largest Philly-proper exit title goes to Avid Radiopharmaceuticals, which in 2010 announced its acquisition by Lilly in a deal valued at up to $800 million.

Founded in 2013, Spark is a publicly traded spinout of Children’s Hospital of Philadelphia (CHOP), which invested $33 million in the company. The Philadelphia Inquirer reports that CHOP stands to reap a total return of $430 million for its minority stake in Spark Therapeutics.

As part of the acquisition deal, the company will remain based out of 3711 Market St., and continue to do business as a standalone Roche company.

“This transaction demonstrates the enormous value that global biotech companies like Roche see in gene therapy, a field in which Philadelphia is the unquestioned leader,” said Saul Behar, senior VP of  advancement and strategic initiatives at the University City Science Center, the West Philly research park where Spark began and grew its operations. “[This] further validates Greater Philadelphia’s status as a biotech hub with a very bright future.”

Spark CEO Jeff Marrazzo said the deep pool of resources from Roche, the company plans to “accelerate the development of more gene therapies for more patients for more diseases and further expedite our vision of a world where no life is limited by genetic disease.”

Advertisement

-30-
JOIN THE COMMUNITY, BECOME A MEMBER
Already a member? Sign in here

Advertisement

A 3D geospatial product is spinning out as its own company with $5M Series A raise

The University City Science Center supported 149 projects and companies in the last year

This North Philly-based ‘ugly’ produce startup just raised $16.5M

SPONSORED

Philly

This financial services firm offers global opportunity in the heart of Philly

Philadelphia

The Philadelphia Inquirer

Mobile Tech Lead

Apply Now
Blue Bell, PA

Pinnacle 21

Senior Software Engineers

Apply Now
Philadelphia

Guru Technologies

Marketing Web Engineer

Apply Now

BIO 2019 was in Philly this week. Here’s what you missed

Why Ben Franklin Technology Partners is fighting for more state funding

Old City medtech startup Strados Labs set to hire after raising $1.8M

SPONSORED

Philly

Guru is taking on growth with deliberate steps and an engaged team

Philadelphia, PA

PromptWorks

Senior UX Designer

Apply Now
601 Lee Road Chesterbrook, PA 19087

Deacom

Web Application Developer

Apply Now
Chesterbrook, PA

Deacom

Software Developer

Apply Now

Sign-up for daily news updates from Technical.ly Philadelphia

Do NOT follow this link or you will be banned from the site!